U.S. Dupixent Market: COPD Expansion, Retail Access, and Competitive Barriers

The U.S. Dupixent market is shaped as much by its pipeline and competitive barriers as by current sales. Polaris Market Research valued the market at USD 11.04 billion in 2024 and projects USD 19.25 billion by 2034, at a CAGR of 5.7% from 2025 to 2034. This article examines where future expansion is expected to come from and why competitors face a steep climb.

Pipeline Focus: Widening the Label

Dupixent’s research and development strategy continues to focus on expanding its label across inflammatory and immune-mediated conditions. Ongoing trials target chronic prurigo nodularis, chronic obstructive pulmonary disease (COPD) with type 2 inflammation, and chronic sinusitis without nasal polyps. Pediatric studies in atopic dermatitis and asthma aim to extend use to younger populations. Sanofi and Regeneron are also exploring roles in rare diseases such as eosinophilic gastritis and food allergies, and Polaris notes that new indications could drive long-term revenue growth and delay biosimilar erosion. Real-world data collection and health economic studies continue to reinforce Dupixent’s value proposition, supporting reimbursement and formulary access through 2033.

Chronic Obstructive Pulmonary Disease: The Fastest-Growing Indication

The chronic obstructive pulmonary disease segment is anticipated to register the highest growth rate during the forecast period. Polaris cites the recent FDA approval for COPD with type 2 inflammation as a significant milestone that opens a new market with millions of U.S. patients, especially older adults with severe symptoms. Phase 3 trials showed promising results in reducing exacerbations in a subset of patients with high type 2 inflammation. Demand is expected to rise as awareness among pulmonologists grows and real-world evidence accumulates.

Bullous Pemphigoid and Other Recent Approvals

Regulatory momentum has been strong. In February 2025, Sanofi and Regeneron announced that the FDA had accepted a supplemental Biologics License Application for Dupixent in bullous pemphigoid under priority review, supported by Phase 3 data. In June 2025, the FDA approved Dupixent for adults with bullous pemphigoid, making it the only targeted medicine for this condition. The report also cites a 2025 FDA approval for chronic spontaneous urticaria, following the LIBERTY-CSU CUPID trial. Orphan drug designations in rare diseases can offer exclusivity extensions and tax credits, making such expansions commercially attractive. Polaris adds that FDA and EMA approvals rely on robust clinical datasets, and that alignment in regulatory pathways and greater reliance on real-world evidence may accelerate approvals and broaden access.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/us-dupixent-market 

Retail Pharmacies Are Expected to Grow Fastest

While hospital pharmacies held the largest distribution share in 2024, retail pharmacies are anticipated to register the highest growth rate during the forecast period. Polaris explains that more patients are transitioning to long-term, self-administered treatment, and subcutaneous injections are available for at-home use. Expanding insurance coverage, easier access to biologics in retail settings, and improved storage logistics support this shift, with patients increasingly preferring to pick up prescriptions from local pharmacies, as does rising patient familiarity across atopic dermatitis, asthma, and soon COPD.

High Barriers and Low Substitution Risk

Polaris describes high entry barriers for biologics. Research and development spending for monoclonal antibodies often exceeds USD 1–2 billion, discouraging smaller firms. Production requires cGMP-compliant facilities, stringent cold-chain logistics, and significant scale, while regulatory requirements and extensive clinical trials add time and risk. With patent protection secured until 2033, the threat from biosimilars remains low.

Substitution risk is also described as low. Corticosteroids and topical therapies do not provide systemic control in severe type 2 inflammatory conditions, and biologics such as tralokinumab and lebrikizumab target only IL-13 and demonstrate narrower efficacy. Most bispecific antibodies under investigation remain in early-phase development. The report characterizes Dupixent as a targeted biologic therapy that fits modern guidelines favoring personalized medicine and reduced long-term steroid use.

Key Players

Sanofi and Regeneron Pharmaceuticals lead the market through their partnership, using regulatory expertise, distribution networks, patient access programs, and real-world evidence to support access across the country. Polaris positions Dupixent as a leader among interleukin inhibitors.

Conclusion

The U.S. Dupixent market is expected to remain an important segment of the specialty biologics landscape, supported by demand for targeted treatments for eligible patients with chronic inflammatory conditions. Greater awareness of disease management and the need for long-term treatment options are contributing to interest in biologic therapies. Clinical research, additional approved indications, and improvements in patient access may influence future market opportunities. Healthcare provider recommendations, insurance coverage, and treatment affordability will remain important factors affecting adoption. Competition from emerging biologics and other advanced therapies may also shape the market environment. Overall, continued clinical evaluation, patient support initiatives, and evolving treatment guidelines are expected to influence the market's trajectory.

More Trending Latest Reports By Polaris Market Research:

Drippers Market

Automotive E-Compressor Market

Hand Sanitizer Market

Cell & Gene Therapy Bioanalytical Testing Services Market

Automotive E-Compressor Market

Platelet Rich Plasma (PRP) Market

Plasma Powder Market

Live Commerce Platforms Market: A Wholesome Shopping Experience

Chillers Market